Researchers have added fresh evidence that early exposure to vaccine-, bacterial- or microbiota-derived antigens has a dramatic effect on the diversity of antibodies an adult mammal will have to fight future infections by pathogens. This antibody diversity is called the clonal repertoire -- basically different single cells with distinct antibody potential that can multiply into a large clone of cells, all producing that distinct antibody.
With more than 140 SARS-CoV-2 vaccines in development, the race is on for a successful candidate to help prevent COVID-19. An effective and safe vaccine would be a major advance in the fight against COVID-19. However, there are challenges in evaluating the efficacy of these vaccines during the pandemic, as an analysis article outlines in CMAJ (Canadian Medical Association Journal).
One of the biggest social media sites -- Facebook -- has allowed "anti-vaxxers" to gain a stronger voice against the use of the human papillomavirus, or HPV, vaccine, according to a new study from a media expert at the University of Missouri.
With no guarantee that a vaccine will be available soon, and even if one is developed it will take considerable time to administer to large numbers of people before the virus is eliminated.
An important line of defense against SARS-CoV-2 is the formation of neutralizing antibodies. These can eliminate the intruders and have great potential to be used for prevention and treatment of SARS-CoV-2 infection. A team of researchers at the Cologne University Hospital and the German Center for Infection Research (DZIF) has elucidated how these antibodies develop and has isolated potent SARS-CoV-2 neutralizing antibodies. Together with Boehringer Ingelheim, these antibodies are currently being further characterized and developed.
MIT engineers are using computing modeling to prevent microparticles from clogging during injections.
The American Cancer Society has updated its guideline for HPV vaccination, adapting a 2019 update from the Federal Advisory Committee on Immunization Practices.
A recent study by Monash University has looked at the role plasma cells and their longevity play in the effectiveness of vaccines in the body and suggests that components within vaccine design are the key.
University of Wisconsin-Madison researchers have developed a safer and more efficient way to deliver a promising new method for treating cancer and liver disorders and for vaccination -- including a COVID-19 vaccine from Moderna Therapeutics that has advanced to clinical trials with humans.
Research out today in the journal Cell shows that a specific change in the SARS-CoV-2 coronavirus virus genome, previously associated with increased viral transmission and the spread of COVID-19, is more infectious in cell culture.